Key result
SB-681323 reduces post-PCI hsCRP elevation by ~37% vs placebo.
RCT (n=92)
Placebo-controlled
Randomized (1:1)
Answers are grounded in this paper and cite their sources.
OBJECTIVE: To evaluate whether a p38α/β mitogen-activated protein kinase inhibitor, SB-681323, would limit the elevation of an inflammatory marker, high-sensitivity C-reactive protein (hsCRP), after a percutaneous coronary intervention (PCI). METHODS AND RESULTS: Coronary artery stents provide benefit by maintaining lumen patency but may incur vascular trauma and inflammation, leading to myocardial damage. A key mediator for such stress signaling is p38 mitogen-activated protein kinase. Patients with angiographically documented coronary artery disease receiving stable statin therapy and about to undergo PCI were randomly selected to receive SB-681323, 7.5 mg (n=46), or placebo (n=46) daily for 28 days, starting 3 days before PCI. On day 3, before PCI, hsCRP was decreased in the SB-681323 group relative to the placebo group (29% lower; P=0.02). After PCI, there was a statistically significant attenuation in the increase in hsCRP in the SB-681323 group relative to the placebo group (37% lower on day 5 [P=0.04]; and 40% lower on day 28 [P=0.003]). There were no adverse safety signals after 28 days of treatment with SB-681323. CONCLUSIONS: In the setting of statin therapy, SB-681323 significantly attenuated the post-PCI inflammatory response, as measured by hsCRP. This inflammatory dampening implicates p38 mitogen-activated protein kinase in the poststent response, potentially defining an avenue to limit poststent restenosis.
No takes yet. Share an insight, caveat, or question.
Sarov‐Blat et al. (2010) conducted an RCT in Coronary artery disease undergoing percutaneous coronary intervention (PCI) (n=92). SB-681323 (p38α/β mitogen-activated protein kinase inhibitor) vs. Placebo was evaluated on Elevation of high-sensitivity C-reactive protein (hsCRP) after PCI (37% lower on day 5; 40% lower on day 28, p=0.04 (day 5); 0.003 (day 28)). SB-681323 attenuated post-PCI hsCRP elevation compared with placebo on day 5 and day 28.
Synapse has enriched 10 related papers. Consider them for comparative context: